Saturday, October 3, 2026

USD/EUR Slides By 2% In The Last 21 Sessions

USD/EUR Slides By 2% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.29% for the last 21 sessions. At 18:10 EST on Monday, 17 April, USD/EUR (USDEUR) is $0.92.

USD/EUR's yearly highs and lows, it's 1.34% up from its 52-week low and 12.707% down from its 52-week high.

News about

  • Usd/jpy traces on sluggish yields below 134.00 even as boj vs. fed divergence regains attention. According to FXStreet on Monday, 17 April, "Not only a lack of major data/events but mixed catalysts and sluggish yields also challenge the USD/JPY pair traders of late.", "Recently, the geopolitical challenges emanating from China, due to its eagerness to collaborate with Russia on global and regional security, as well as tussles with the US over Taiwan, prod the market sentiment and weigh on the USD/JPY pair."
  • Usd/jpy eases from over one-month peak, trades with modest gains just below 134.00. According to FXStreet on Monday, 17 April, "This, along with the US bond yields, should influence the USD price dynamics and provide some impetus to the USD/JPY pair. ", "Expectations that the Federal Reserve (Fed) will pause its rate-hiking cycle, sooner rather than later, fail to assist the US Dollar (USD) to capitalize on its recovery move from a one-year low, which, in turn, acts as a headwind for the USD/JPY pair. "
  • Usd/jpy price analysis: gains momentum on rising US treasury bond yields. According to FXStreet on Monday, 17 April, "Conversely, if the USD/JPY retraces, the first support would be 100-day EMA at 134.00. ", "The USD/JPY extended its gains past the last week's high of 134.04, and it's aiming to challenge a break above January 6 high at 134.77. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com